Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1467-1474

  Jo, Solomon ^a   Juhasz, Agnes ^a   Zhang, Keqiang ^a   Ruel, Christopher ^a   Loera, Sofia ^a   Wilczynski, Sharon P ^a   Yen, Yun ^a   Liu, Xiyong ^a   Ellenhorn, Joshua ^a   Lim, Dean ^a   Paz, Benjamin ^a   Somlo, George ^a   Vora, Nayana ^a   Shibata, Stephen ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Human papillomavirus; Hypoxia inducible factor 1 ; Oropharyngeal squamous cell carcinoma; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; INFECTION RISK; LARYNX CARCINOMA; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TREATMENT RESPONSE; VERRUCA VULGARIS;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DNA PRIMERS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 67650079783     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Walboomers JM, Jacobs MV, Manos MM et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999. (Pubitemid 29406813)
2. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248(4951): 76-79, 1990. (Pubitemid 20139274)
3. Storey A, Pim D, Murray A et al: Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 7: 1815-1820, 1988.
4. Syrjänen K, Syrjanen S, Lamberg M, Pyrhönen S and Nuutinen J: Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surgery 12: 418-424, 1983. (Pubitemid 14141093)
5. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV and Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720, 2000. (Pubitemid 30365531)
6. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956, 2007. (Pubitemid 46740304)
7. Paz IB, Cook N, Odom-Maryon T, Xie Y and Wilczynski SP: Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 79: 595-604, 1997.
8. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE and Weichselbaum RR: Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 2: 755-762, 1996. (Pubitemid 26133472)
9. Schwartz SR, Yueh B, McDougall JK, Daling JR and Schwartz SM: Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 125: 1-9, 2001. (Pubitemid 33661083)
10. Lindel K, Beer KT, Laissue J, Greiner RH and Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92: 805-813, 2001. (Pubitemid 32783066)
11. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M and Kelsey KT: Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8: 3187-3192, 2002. (Pubitemid 35155029)
12. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP and Haugen TH: Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104: 336-344, 2003. (Pubitemid 36249816)
13. Mellin H, Friesland S, Lewensohn Dalianis RT and Munck-Wikland E: Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89: 300-304, 2000. (Pubitemid 30430748)
14. Fakhry C, Westra WH, Li S, Cmelak A, Ridge J, Pinto H, Forastiere A and Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008.
15. Cohen NA, Lai SY, Ziober AF and Ziober BL: Dysregulation of hypoxia-inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope 114: 418-423, 2004. (Pubitemid 38391902)
16. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S and Herlyn M: Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Ca Res 5: 775-782, 1999. (Pubitemid 29180828)
17. López-Ocejo O, Viloria-Tetit A, Bequet-Romero M, Mukhopadhyay D, Rak J and Kerbel RS: Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53-independent manner. Oncogene 19: 4611-4620, 2000.
18. Kim SH, Juhnn YS, Kang S, Park S, Sung MW, Bang YJ and Song YS: Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell Mol Life Sci: CMLS 63: 930-938, 2006.
19. Tang X, Zhang Q, Nishitani J, Brown J, Shi S and Le AD: Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13: 2568-2576, 2007. (Pubitemid 46795128)
20. Wilczynski SP, Lin BT, Xie Y and Paz IB: Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 152: 145-156, 1998. (Pubitemid 28028055)
21. Chan PK, Chan DP, To KF, Yu MY, Cheung JL and Cheng AF: Evaluation of extraction methods from paraffin wax-embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 54: 401-403, 2001. (Pubitemid 32458142)
22. Herrero R, Castellsagué X, Pawlita M et al: Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95: 1772-1783, 2003. (Pubitemid 38008900)
23. Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK, Spitz MR, Schiller JT, Wei Q and Sturgis EM: Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: A matched-pair analysis. Clin Ca Res 9: 2620-2626, 2003.
24. Kreimer AR, Clifford GM, Boyle P and Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Previa: 467-475, 2005. (Pubitemid 40270113)
25. Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA and Cooper DL: Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22: 3061-3069, 2004. (Pubitemid 41103718)
26. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, Gopal HV, Costello R, Read R, Adak S and Posner MR: Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 25: 153-159, 2002. (Pubitemid 34293068)
27. Mathur RS and Mathur SP: Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV E6 in HPV-positive cancers. Gynecol Oncol 97: 206-213, 2005.
28. Bermont L, Lamielle F, Fauconnet S, Esumi H, Weisz A and Adessi GL: Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. Int J Cancer 85: 117-123, 2000.
29. Kim SH, Loo BS, Kang S, Park K, Kim H, Lee KR, Lee MJ, Kim JM, Choi EC and Cho NH: HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 120: 1418-1425, 2007. (Pubitemid 46355375)
30. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL and Psyrri A: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24: 736-747, 2006. (Pubitemid 46622040)
31. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR and Brakenhoff RH: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25: 2558-2564, 2006.
32. Braakhus BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR and Brakenhoff RH: Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96: 998-1006, 2004. (Pubitemid 39162642)